The Evidence Spectrum
Longevity peptide research spans an enormous range of evidence quality. Some compounds have decades of research across multiple species. Others have a handful of in vitro studies. Being honest about where each compound falls on this spectrum is essential for informed decision-making.
Strongest Evidence: Sermorelin
Sermorelin has the most developed evidence base of any GH-related longevity compound, including genuine FDA clinical data from its 1997 approval. Human studies demonstrate GH and IGF-1 stimulation. The mechanism is well understood. This is as close to established as anything in this space gets.
Solid Preclinical Evidence: MOTS-c
MOTS-c’s 2021 Nature Aging study showing exercise-like metabolic effects in aged mice is methodologically rigorous and from a reputable research group (USC). The mitochondrial DNA origin makes the mechanism biologically compelling. Human data is early-stage.
Intriguing But Narrower Base: Epitalon
Epitalon has 30 years of research primarily from one institution in Russia. The telomerase activation finding is significant if it replicates. The concentration of research at a single institution is a meaningful limitation — not disqualifying, but worth noting.
The Honest Bottom Line
None of these compounds have proven human longevity effects in the sense of controlled trials showing extended lifespan. What they have is biologically plausible mechanisms and animal or in vitro data that supports further investigation. Physician-supervised use as part of a comprehensive longevity program is defensible — marketing them as proven life-extension therapies is not.